CVBF – Consorzio per Valutazioni Biologiche e Farmacologiche

Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) is a not-for-profit organisation, founded in 2000 with the mission to perform research and provide scientific, economic and regulatory consultancy for innovation in the health sector at European level. The main fields of interest are life sciences and biotechnologies, drug development for small populations (pediatric and rare diseases), research management andmethodology, monitoring, statistics, regulatory, ethics and pharmacovigilance.

Who we are

About

Mission

Consortium

CVBF Albania

Accreditations

Activities

Scientific Research

Development and application of innovative methodologies in clinical trials for small populations, management of disease registries, execution of studies in the pharmacological field. Find out more.

Regulatory Activities

Development and supervision of dossiers and documentation regarding national and European authorisation procedures for medicinal products. Find out more.

Clinical Trials

Development and management of all clinical trial phases, which are performed by the Consortium both as a Sponsor and as a Contract Research Organisation (CRO). Find out more.

Training

Educational activities addressed to public bodies, research institutes and private companies, also within CME programmes. Find out more.

Project Management

Management and participation to medical research projects and consortiums at national and international level. Find out more.

Databases

Design and management of registries and drug databases. Find out more.

Networking

Research networks aimed to facilitate transfer of know-how and to promote national and international research as well as scientific excellence. Find out more.

CVBF Brochure

On-going Projects

Latest News

1610, 2018

CORDIS has published a new article on DEEP Project

CORDIS has recently published the article “DEEP project - "Success story" for European Commission's DG Research and Innovation”. The article underlines the successful outcomes of DEEP (DEferiprone Evaluation in Paediatrics), project coordinated by Consorzio per Valutazioni [...]

810, 2018

EMA Committee for Orphan Medicinal Products (COMP) elects new chair

The European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has elected Dr Violeta Stoyanova-Beninska as its new chair for a three-year mandate. She follows Professor Bruno Sepodes who served as COMP chair for two [...]

CVBF is one of the Financial Times 1000 Europe’s Fastest Growing Companies 2018